Summary
Bristol-Myers Squibb Company (BMY) announced significant leadership changes via an 8-K filing on December 21, 2016. Lamberto Andreotti, a member of the Board of Directors, has informed the company that he will not seek re-election at the 2017 Annual Meeting of Stockholders. This marks the end of his tenure on the board. In conjunction with this, the Board of Directors has elected Giovanni Caforio, M.D., the current Chief Executive Officer, to the position of Chairman of the Board, effective May 2, 2017. Dr. Caforio will consolidate his leadership role, serving concurrently as both CEO and Chairman of the Board. Investors should note this transition as a key leadership development within the company.
Key Highlights
- 1Lamberto Andreotti will not stand for re-election to the Board of Directors at the 2017 Annual Meeting.
- 2The 2017 Annual Meeting is expected to be held on May 2, 2017.
- 3Giovanni Caforio, M.D., current CEO, has been elected Chairman of the Board.
- 4Dr. Caforio's appointment as Chairman is effective May 2, 2017.
- 5Dr. Caforio will hold both the CEO and Chairman of the Board positions concurrently.
- 6A press release detailing these changes is attached as Exhibit 99.1.
Frequently Asked Questions
Lamberto Andreotti will retire from the Board of Directors at the 2017 Annual Meeting, and Giovanni Caforio, M.D. (the current CEO), will become Chairman of the Board effective May 2, 2017, in addition to his CEO role.
The leadership changes are scheduled to take effect on May 2, 2017, which is also the expected date of the 2017 Annual Meeting of Stockholders.
Yes, Giovanni Caforio, M.D. will serve as both Chief Executive Officer and Chairman of the Board of Directors concurrently starting May 2, 2017.
The filing specifically states that Lamberto Andreotti will not stand for re-election to the Board of Directors. It does not mention his departure from any other roles within the company, if he holds any.